Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., ...

Trump has hailed the Regeneron therapy as a cure for the virus, but the company’s CEO Leonard Schleifer was quick to point out that the scientific evidence is not there to support the claim.

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of ...

CEO Leonard Schleifer highlighted 10% revenue growth ... expressed increased concerns about competitive pressures on EYLEA.

Regeneron’s Co-Founder, President and CEO, Leonard Schleifer, stated: "we anticipate these enhancements will lead to an acceleration in Eylea HD uptake starting in the second half of this year." ...

the acquisition of Checkmate will add a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers," said Leonard Schleifer, Regeneron's chief executive ...

Regeneron Pharmaceuticals Inc.’s stock ... On a call with analysts, Chief Executive and co-Founder Leonard Schleifer said the U.S. Food and Drug Administration has requested more data from ...

Regeneron Pharmaceuticals ... The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown ...